SOURCES SOUGHT
A -- : Research and Development Sources Sought – HIV Germany Cohort Study
- Notice Date
- 8/25/2017
- Notice Type
- Sources Sought
- NAICS
- 541712
— Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
- Contracting Office
- Department of the Army, U.S. Army Medical Research Acquisition Activity, U.S. Army Medical Research Acquisition Activity, Attn: MCMR-AAA, 820 Chandler Street, Frederick, MD 21702-5014, Maryland, 21702-5014, United States
- ZIP Code
- 21702-5014
- Solicitation Number
- W81XWH-17-R-0061
- Archive Date
- 9/26/2017
- Point of Contact
- Dana M. Kavitski, , Kelly R. Green, Phone: 3016191346
- E-Mail Address
-
dana.kavitski.civ@mail.mil, kelly.r.green.civ@mail.mil
(dana.kavitski.civ@mail.mil, kelly.r.green.civ@mail.mil)
- Small Business Set-Aside
- N/A
- Description
- 1.0 GENERAL INFORMATION: The following notice constitutes a Sources Sought Notice and a Notice of Intent to Sole Source in accordance with FAR 5.203(a), 5.205(a) and 19.202-2. The government is seeking responses from potential sources to meet this requirement, however, if no other capable sources are identified, it is the Government's intent to award a sole source contract to the Institut für HIV Forschung (Institute for HIV Research) Universitätsklinikum Essen (AöR) Universität Duisburg-Essen (University of Duisburg-Essen), Virchowstr.171, D-45147 Essen, for the requirement outlined in this notice. This is a notification that the US Army Medical Research Acquisition Activity (USAMRAA) in support of the US Army Medical Materiel Development Activity (USAMDAA) intends to award a sole source contract under statutory authority 10 U.S.C. 2304(c)(1) as implemented by FAR 6.302-1, Only One Responsible Source and No Other Supplies or Services Will Satisfy the Agency Requirements. The associated North American Industry Classification System (NAICS) code for this procurement is 541712 with a size standard of 1,000 employees. 2.0 DISCLAIMER: This Sources Sought Notice is issued solely for information and planning purposes and does not constitute a solicitation. Neither unsolicited proposals nor any other kind of offers will be considered in response to this notice. Responses to this notice are not offers and will not be accepted by the Government to form a binding contract. Responders are solely responsible for all expenses associated with responding. All information received in response to this notice that is marked proprietary will be handled accordingly. Responses will not be returned. At this time, questions concerning the composition and requirements for a future RFP will not be entertained. 3.0 SUBJECT: In support of the USAMMDA's mission to develop a subtype B HIV vaccine, this sources sought notice is seeking entities capable of providing assistance in executing an observational study entitled "Longitudinal incidence study in subtype B-prevalent region among men who have sex with men at risk for HIV infection to determine feasibility of HIV vaccine efficacy trials". This study will be executed in Germany at pre-selected clinical sites with support from several research laboratories. 4.0 DESCRIPTION: The US Army is pursuing development of a subtype B HIV vaccine and is interested in developing potential clinical sites for future efficacy studies. The HIV epidemic in Germany is predominantly subtype B, similar to the epidemic in US military personnel and in the general US population. The establishment of new sites in Germany will augment those already available in the US, and will ensure that the Army has sufficient numbers of clinical sites for future HIV vaccine efficacy trials. In order to develop new sites and train staff to conduct HIV vaccine trials, an observational cohort study in the target population will be executed. The University of Duisberg-Essen has recruited investigators throughout Germany to conduct the cohort study, which will enroll 1000 men who have sex with men and transgender women to determine the incidence of HIV infection and their willingness to participate in a vaccine trial. The University of Duisberg-Essens' Institute for HIV Research has established a collaboration with the German government Robert Koch Institute (equivalent to the US CDC), the Center for Infectious Disease Research (DZIF), the University of Cologne, and other non-governmental organizations to develop co-funding mechanisms to support the objectives of the cohort study. The University of Duisberg-Essen has been instrumental in bringing together academic, government and non-governmental organizations to support this study, resulting in cost-sharing agreements for multiple diagnostic assays, research assays, and site costs. This co-funding is available only with the collaborations achieved by the University of Duisberg-Essen; otherwise, the Government would be required to bear the full cost of the study. In addition, investigators at the sites in each city have agreed to collaborate on this study, saving an estimated 6 to 12 months for site recruitment. The University of Duisberg-Essen is uniquely positioned to support the US Military in its development of a subtype B vaccine because of the Institute led by Dr. Streeck, and the collaborations already established within Germany. 5.0 SUBMISSION INSTRUCTIONS: All responses to this notice shall be via e-mail to the point of contact below. Telephone questions or inquiries will not be answered or accepted. Entities interested in submitting a response must furnish in writing, a 2-3 page (not including cover page, index or list of references) synopsis of their capability to perform the tasks described above, and a Rough Order of Magnitude (ROM) estimate of the cost to perform the services. Companies responding to this notice must provide complete contact information (Company name, Address, Point of Contact, telephone, email address, CAGE Code and DUNS number). Responders must identify their company's business size (based on the NAICS size standard), business status (i.e. small business, disadvantaged, HUB zone, woman owned, service disabled veteran owned). Please also include information regarding any prior experience with U.S. Government contracts and favorable experience working with the FDA. Responders must have an active profile in in the System for Award Management (SAM) and must have current representations and certifications uploaded into their active SAM profile. See https://www.sam.gov for details/instructions. Responses must be sent to later than 12:00PM Eastern Time on 11 Sept 2017. 6.0 SUBMISSION POINT OF CONTACT: Interested entities shall forward submissions to Dana Kavitski, Contract Specialist, at dana.kavitski.civ@mail.mil.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/USA/USAMRAA/DAMD17/W81XWH-17-R-0061/listing.html)
- Record
- SN04647470-W 20170827/170825231647-d8573e9941ed50dc5d3e4ae41f147c96 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |